Mysimba® Allows for Full Titration Within 1 Month

Standard posology for Mysimba® (8 mg/90 mg)1‡

  • Mysimba® is a convenient, oral option in combination with diet and exercise1
A horizontal table that details the dosing titration schedule for Mysimba®. The table is broken into AM on the top half and PM on the bottom half and uses an orange-to-white gradient.

Not actual tablet size.

‡Please refer to the Mysimba® Physician Prescribing Checklist to assess your patient’s suitability for Mysimba® treatment. Tablet should be swallowed whole with water and preferably taken with food. Tablets should not be cut, chewed or crushed.

Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

Dosing adjustments

Use with caution in patients over 65 years of age and not recommended in patients over 75 years of age. For patients with Diabetes or elderly individuals assess eGFR prior to initiating treatment. For patients with hepatic or renal impairment, maximum recommended daily doses are as follows:

  • Moderate or severe renal impairment: 2 tablets per day (1 in the AM, 1 in the PM).
  • Mild hepatic impairment: 2 tablets per day (1 in the AM, 1 in the PM).

Not recommended in moderate hepatic impairment.

Contraindicated in end-stage renal failure and severe hepatic impairment

References:

  1. Mysimba® SmPC available at https://www.medicines.org.uk/emc/product/2684/smpc#gref accessed September 2026
Reporting adverse effects: Adverse effects should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively you can report a suspected adverse drug reaction to the Yellow Card scheme by calling 0800 731 6789 Adverse events should also be reported to Orexigen®: +44 20 3966 0116 or currax.mi@primevigilance.com.
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014